HR+/HER2+ breast cancer: FDA approves a chemotherapy-free maintenance treatment. A journey from biology to therapy

A research line long pursued by Fondazione Michelangelo led to FDA approval of palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for HR+/HER2+ locally advanced or metastatic breast cancer